Subjective sleep quality in lung cancer patients before and after chemotherapy

2013 ◽  
Vol 4 (2) ◽  
pp. 138-142 ◽  
Author(s):  
Paul Zarogoulidis ◽  
Paschalis Steiropoulos ◽  
Eleni Perantoni ◽  
Konstantinos Archontogeorgis ◽  
Ellada Eleftheriadou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Sleep Quality ◽  
Cancer Patients ◽  
Subjective Sleep Quality ◽  
Lung Cancer Patients ◽  
Subjective Sleep ◽  
Before And After

scholarly journals Comparison of Sleep Quality before and after Chemotherapy in Locally Advanced Nonsmall Cell Lung Cancer Patients: A Prospective Study

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
N. Belloumi ◽  
S. Maalej Bellaj ◽  
I. Bachouche ◽  
F. Chermiti Ben Abdallah ◽  
S. Fenniche
Keyword(s):  
Lung Cancer ◽  
Sleep Quality ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Sleep Disturbances ◽  
Locally Advanced ◽  
Nonsmall Cell Lung Cancer ◽  
Poor Sleep ◽  
Lung Cancer Patients ◽  
Before And After

Background. Preservation of sleep quality is a modifiable and treatable factor, which may enhance the patient’s adherence to other supportive and palliative care procedures. The outcome of sleep disturbances in lung cancer patients before and after treatment aren’t reported. The aim of this study was to investigate changes in sleep quality before and after chemotherapy in locally advanced or metastatic NSCLC patients. Methods. It was a prospective study including 64 patients with stage III or IV nonsmall-cell lung cancer. Patients answered the Tunisian dialectal version of the following questionnaires: PSQI and QLQ-C30 in order to evaluate, respectively, the sleep quality and the quality of life. The assessments took place before chemotherapy and then repeated after the chemotherapy course was over. Results. The mean age was 62.9 years. All patients were active smokers. Before chemotherapy, there were 10 patients (15%) with poor sleep quality. The most frequent complaints were daytime sleepiness (70%) and nocturnal arousals (100%). After chemotherapy, the mean PSQI score increased from 2.9 to 5.4, and 45% of all patients had poor sleep quality. Most frequent complaints were the extension of sleep latency (69%), daytime sleepiness (98%), and nocturnal arousals (100%). Predicting factors of sleep disturbance according to statistical univariate analysis were delayed diagnosis confirmation (p=0.05), delayed treatment onset (p<10−3), depressive mood (p=0.001), and anxious mood (p=0.001). Multivariate analysis had shown a significant and independent correlation between sleep quality and shortened diagnosis and treatment delays. Sociodemographic parameters, clinical parameters, and factors related to treatment procedure had no correlation with sleep quality. Conclusions. Our study demonstrates the persistence and potential intensity worsening of sleep disturbances in advanced stage nonsmall-cell lung cancer patients. We, hereby, reported a statistical correlation between sleep quality and quality of life in our patients.

scholarly journals Self-reported sleep quality as prognostic for survival in lung cancer patients

2020 ◽  
Vol Volume 12 ◽  
pp. 313-321 ◽  
Author(s):  
Teodor Gottfried ◽  
Iris Kamer ◽  
Iris Salant ◽  
Damien Urban ◽  
Yaacov R Lawrence ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Sleep Quality ◽  
Cancer Patients ◽  
Lung Cancer Patients

Anti-dementia and anti-hyperlipidemic medication use at end of life in elderly lung cancer patients: Analysis of SEER-Medicare data.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10027-10027 ◽  
Author(s):  
Min Ji Kim ◽  
Zhigang Duan ◽  
Hui Zhao ◽  
Holly Michelle Holmes ◽  
Joanna-Grace Mayo Manzano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Use ◽  
End Of Life ◽  
Cancer Patients ◽  
Cholesterol Absorption ◽  
Study Endpoint ◽  
Lung Cancer Patients ◽  
Bile Acid Sequestrants ◽  
Before And After ◽  
Hospice Use

10027 Background: Despite risk for polypharmacy, elderly cancer patients may receive drugs whose time to benefit likely exceeds life expectancy. This study aims to describe use of drugs considered potentially unnecessary, namely anti-hyperlipidemics and anti-dementia drugs, and to identify factors associated with their use in Stage 3 or 4 non-small cell lung cancer (NSCLC) patients approaching end of life. Methods: We identified all patients older than 65 diagnosed with primary Stage 3 or 4 NSCLC between 2006 and 2011 in the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Information on drug prescriptions was extracted from Medicare Part D files. First-time hospice enrollment or death date was used as the final endpoint in analysis. The primary outcome was use of drugs of interest at 4 months before NSCLC diagnosis, 6 months and 3 months before death or hospice. Associations with demographic or other factors were tested using the Pearson χ2 test. Results: Of all 7983 patients, 45.1% were taking statins before diagnosis, while 40.7% and 30.9% were still taking statins at 6 and 3 months before death or hospice. Use of bile acid sequestrants, fibric acid derivatives, and cholesterol absorption inhibitors were found to decrease toward death or hospice. In contrast, anti-dementia drug use did not decrease, with 3.4% before diagnosis and 4.2% and 3.5% at 6 and 3 months before death or hospice. Approximately 30% of anti-dementia medications were newly prescribed at 6 and 3 months before study endpoint. Having a higher number of prescriptions at 3 months before death or hospice was associated with higher rates of drug use both before and after cancer diagnosis. Having a higher Charlson comorbidity index correlated with greater anti-dementia drug use before diagnosis. Demographic, socioeconomic, and treatment factors were not found to be correlated with drug use. Conclusions: A high prevalence of statin use persists while a notable proportion of anti-dementia drugs are newly prescribed toward death or hospice. Our findings suggest an opportunity for clinicians to re-evaluate risks and benefits of potentially unnecessary medications in elderly patients nearing end of life.

scholarly journals Sleep Quality in Lung Cancer Patients

2013 ◽  
Vol 14 (5) ◽  
pp. 2909-2913 ◽  
Author(s):  
Ruveyda Gelisken Akyuz ◽  
Ozlem Ugur ◽  
Ayfer Elcigil
Keyword(s):  
Lung Cancer ◽  
Sleep Quality ◽  
Cancer Patients ◽  
Lung Cancer Patients

scholarly journals INTESTINAL MICROBIOCENOSIS AND CYTOKINE STATUS IN LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY

2017 ◽  
Vol 20 (3) ◽  
pp. 152-157
Author(s):  
Margarita Yu. Serkova ◽  
E. B Avalueva ◽  
I. G Bakulin ◽  
S. I Sitkin
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Intestinal Microflora ◽  
Control Group ◽  
Gas Liquid Chromatography ◽  
Lung Cancer Patients ◽  
Before And After ◽  
Oncological Diseases ◽  
Intestinal Microbiocenosis

In patients with oncological diseases chemotherapy leads to the damage of a mucous membrane of gastrointestinal tract, as well as to a deterioration of the intestinal microbiocenosis. The article presents the changes in intestinal microbiocenosis in lung cancer patients, chemotherapy, the nature of the influence appointed in the schemes of the treatment of lung cancer, impact of anticancer drugs on the state of the intestinal microflora, and the improvement of technologies of treatment of lung cancer patients receiving chemotherapy on the basis of supplementation of the complex therapy by the probiotics Material and methods. 41 lung cancer patient receiving the first line of the first cycle of chemotherapy was included. The age of patients varied from 49 to 73 years, the average duration of the disease was 1 year. Patients from the main group (n = 21) received probiotics treatment together with the chemotherapy course. Patients from the control group (n = 20) received only chemotherapeutic preparations. All patients were observed before and after treatment, the study of metabolites of intestinal microorganisms in blood was performed by the method of the gas-liquid chromatography - mass-spectrometry by G.A. Osipov’s method, determination of cytokine status multiplex method. The efficiency of probiotic therapy was evaluated by results of the dynamics of studied indices. Results. The deterioration in intestinal microflora was manifested as the decreased quantity of Lactobacillus, Bifidobacterium, and increased quantity of different pathogenic microorganisms. It was noted decreased rate in the improvement of composition intestinal microflora after the treatment course with the metabiotic. Conclusion. Using of metabiotic medicines with the chemotherapy in lung cancer patients is promising to prevent deterioration of the gut microflora.

Sign in / Sign up

Export Citation Format

Share Document